Xenon製藥 XENE 深 滬
等待開盤 10-29 09:30:00 美东时间
42.53
+0.640
+1.53%
華盛通- 最 高42.74
- 今 開41.78
- 成交量 69.98万股
- 最 低 41.405
- 昨 收 41.89
- 總市值 32.79亿
- 52周最高 45.45
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 26.74
- 委 比 -94.94%
- 總股本 7710.58万
- 歷史最高 50.99
- 量 比 0.83
- 振 幅 3.19%
- 歷史最低 2.10
- 每 手 1
- 風險率 4.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenon appoints Tucker Kelly as CFO
Xenon Pharmaceuticals (NASDAQ:XENE) announced on Thursday the appointment of Tucker Kelly as Chief Financial Officer and member of the Xenon senior executive team. Kelly is an executive who brings e...
10-16 20:48
Xenon Pharmaceutical Appoints Tucker Kelly CFO, Effective Oct. 15, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
10-16 20:32
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target
Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $55 price target.
10-07 19:45
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
Xenon Pharmaceuticals will host an investor webinar on October 6, 2025, to discuss its early-stage programs targeting Kv7 and Nav1.7 for non-opioid pain treatments. The webinar, titled "Developing Novel Non-Opioid Treatments for Pain," will run from 11:30 AM to 12:30 PM Eastern Time. Investors can register via the provided link and submit questions during the session or beforehand. A replay will be available on the company's website after the eve...
09-25 20:01
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $55 price target.
09-02 21:30
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $43
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $42 to $43.
08-12 21:27
Xenon Completes Patient Recruitment for Phase 3 Study
Xenon ( ($XENE) ) has shared an update. Xenon Pharmaceuticals reported its seco...
08-12 04:43
